In preclinical models, antiviral better inhibits COVID-19 than Remdesivir; further studies warranted

(American Association for the Advancement of Science) Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news